LONDON (Reuters) - Britain's BTG said it would make two acquisitions, one extending its expertise in liver cancer and the other a treatment for severe blood clots, to create an interventional medicine business with potential sales of $1 billion. <\/p>\n
The company said on Thursday it had agreed to buy the targeted therapies division of Nordion Inc, for about $200 million in a deal that adds Therasphere radioactive glass beads treatment for liver cancer to its chemotherapy beads unit. <\/p>\n
It is also buying EKOS Corp for an initial $180 million, and up to $40 million in future payments depending on achieving milestones, to gain an interventional treatment for severe blood clots. <\/p>\n
Some of the cost of buying the Nordion unit will come from the placing of 32.8 million new shares, representing just under 10 percent of BTG's share capital. <\/p>\n
Chief Executive Louise Makin said the deals would position BTG as a leading player in the rapidly growing interventional medicine market. <\/p>\n
\"By adding TheraSphere and EkoSonic into our current portfolio of oncology beads and Varisolve (PEM), our board's vision is to create an Interventional Medicine business with potential sales of $1 billion,\" she said. <\/p>\n
(Reporting by Paul Sandle; editing by James Jukwey) <\/p>\n
<\/p>\n
More here:<\/p>\n
BTG builds interventional medicine platform with deals<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" LONDON (Reuters) - Britain's BTG said it would make two acquisitions, one extending its expertise in liver cancer and the other a treatment for severe blood clots, to create an interventional medicine business with potential sales of $1 billion. The company said on Thursday it had agreed to buy the targeted therapies division of Nordion Inc, for about $200 million in a deal that adds Therasphere radioactive glass beads treatment for liver cancer to its chemotherapy beads unit. It is also buying EKOS Corp for an initial $180 million, and up to $40 million in future payments depending on achieving milestones, to gain an interventional treatment for severe blood clots Continue reading